Future concepts in bronchodilation for COPD: dual-versus monotherapy
D Singh, JF Donohue, IH Boucot… - European …, 2021 - Eur Respiratory Soc
Most patients with COPD are recommended to initiate maintenance therapy with a single
long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2 …
long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2 …
When is dual bronchodilation indicated in COPD?
M Thomas, DMG Halpin… - International Journal of …, 2017 - Taylor & Francis
Inhaled bronchodilator medications are central to the management of COPD and are
frequently given on a regular basis to prevent or reduce symptoms. While short-acting …
frequently given on a regular basis to prevent or reduce symptoms. While short-acting …
Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world'study
CF Vogelmeier, H Worth, R Buhl, CP Criée… - Respiratory …, 2022 - Springer
Introduction Chronic obstructive pulmonary disease (COPD) guidelines recommend
reserving triple therapy of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and …
reserving triple therapy of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and …
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial
CF Vogelmeier, EM Kerwin… - Therapeutic …, 2020 - journals.sagepub.com
Rationale: Symptom relief is a key treatment goal in patients with chronic obstructive
pulmonary disease (COPD). However, there are limited data available on the response to …
pulmonary disease (COPD). However, there are limited data available on the response to …
Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
R Buhl, CP Criée, P Kardos… - … Journal of Chronic …, 2018 - Taylor & Francis
Background No observational studies have evaluated the “real-world” effectiveness of dual
bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic …
bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic …
[HTML][HTML] The role of fixed-dose dual bronchodilator therapy in treating COPD
A Anzueto, M Miravitlles - The American journal of medicine, 2018 - Elsevier
The incidence of chronic obstructive pulmonary disease (COPD) is rising in the United
States, and the disease represents a significant source of morbidity and mortality. Primary …
States, and the disease represents a significant source of morbidity and mortality. Primary …
Dual bronchodilator in the era of triple therapy
AI Papaioannou, S Loukides, P Bakakos… - … Journal of Chronic …, 2020 - Taylor & Francis
Pharmacological medications used for the treatment of COPD patients have increased
significantly. Long-acting bronchodilators have been recognized as the mainstay of the …
significantly. Long-acting bronchodilators have been recognized as the mainstay of the …
Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
J Voorham, M Corradi, A Papi… - ERJ Open …, 2019 - Eur Respiratory Soc
This real-world study compared the effectiveness of triple therapy (TT; long-acting
muscarinic antagonists (LAMAs)/long-acting inhaled β-agonists (LABAs)/inhaled …
muscarinic antagonists (LAMAs)/long-acting inhaled β-agonists (LABAs)/inhaled …
Dual bronchodilation in COPD: lung function and patient-reported outcomes–a review
D Price, A Østrem, M Thomas… - International journal of …, 2016 - Taylor & Francis
Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting
muscarinic antagonist [LAMA] plus a long-acting β2-agonist [LABA]) are available for the …
muscarinic antagonist [LAMA] plus a long-acting β2-agonist [LABA]) are available for the …
Single-inhaler triple versus dual bronchodilator therapy in COPD: real-world comparative effectiveness and safety
Purpose Randomized trials report that single-inhaler triple therapy is more effective than
dual bronchodilators at reducing exacerbations in patients with chronic obstructive …
dual bronchodilators at reducing exacerbations in patients with chronic obstructive …